Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: RTOG 1205 Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

 


RTOG 1205 Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma


Trial Focus

Brain and Nervous System Tumors

Objective

         This is a clinical trial of investigational drug Bevacizumab which will be administered intravenously.

IRB Protocol #

13-3160

Trial Status

OPEN

Principle Investigator

BRIAN KAVANAGH

Sponsor

RTOG

Contact

MONICA ROBISCHON at (720) 848-0661 or MONICA.ROBISCHON@UCDENVER.EDU

Location

Dept Of Veterans Affairs Medical Center University of Colorado Hospital Dept Of Veterans Affairs Medical Center University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. This study will have 2 different groups of research subjects like you. A computer program will place you in one of the study groups. If you are in group 1, you will receive bevacizumab alone. The bevacizumab will be given by vein every 2 weeks for as long as it is working and there are no intolerable side effects. If you are in group 2, you will receive bevacizumab and radiation therapy. The bevacizumab will be given by vein every 2 weeks for as long as it is working and there are no intolerable side effects. You will receive 10 treatments of radiation, which will be delivered daily (typically 5 treatments per week), for 2 weeks. // Eligibility criteria include but are not limited to 18 years or older with recurrent glioblastoma.Eligibility criteria include but are not limited to 18 years or older with recurrent glioblastoma.